nct04437511

Donanemab in Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) {#donanemab-trial}

Overview {#overview}

Assessment of Safety, Tolerability, and Efficacy of [Donanemab](/entities/donanemab) in Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 2)

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[@novel2024].

Alzheimer's Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[@alzheimers2023].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04437511 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1736 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2020-06-19 00:00:00 |
| Completion Date | 2028-11-01 00:00:00 |
| Last Updated | 2025-08-29 00:00:00 |

Conditions Studied

• Alzheimer Disease

Scientific Background

Disease Context

...

Donanemab in Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) {#donanemab-trial}

Overview {#overview}

Assessment of Safety, Tolerability, and Efficacy of [Donanemab](/entities/donanemab) in Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 2)

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[@novel2024].

Alzheimer's Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[@alzheimers2023].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04437511 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1736 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2020-06-19 00:00:00 |
| Completion Date | 2028-11-01 00:00:00 |
| Last Updated | 2025-08-29 00:00:00 |

Conditions Studied

• Alzheimer Disease

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Therapeutic Mechanism

The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].

Key features of the Phase 3 design include:

• Randomization: Participants are randomly assigned to treatment or placebo groups
• Double-blind: Neither participants nor investigators know the treatment assignment
• Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
• Controlled design: Comparison against placebo provides clear evidence of treatment effect

Outcome Measures

Primary Endpoints

• Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)
• Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

• Gilbert, Arizona, United States
• Phoenix, Arizona, United States
• Phoenix, Arizona, United States
• Scottsdale, Arizona, United States
• Sun City, Arizona, United States

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

Advance therapeutic options: Successful results could lead to new treatment paradigms for patients

Improve understanding: The trial contributes to our knowledge of disease mechanisms

Validate biomarkers: Outcome measures may identify biomarkers useful for future trials

Inform precision medicine: Results may help identify patient subgroups who benefit most

The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

Donanemab: Anti-Amyloid Antibody Mechanism {#mechanism}

Target and Binding Properties

Donanemab is a monoclonal antibody developed by Eli Lilly that specifically targets pyroglutamate-modified amyloid-beta (pE3-Aβ) plaques in the brain. This target represents a specific form of amyloid that is particularly abundant in Alzheimer's disease brains and is considered an early and persistent component of plaque pathology[@donanemab2024].

The antibody's mechanism involves:

• Binding to pE3-Aβ: Donanemab recognizes amyloid-beta peptides with an N-terminal pyroglutamate modification (AβpE3), which is found specifically in dense core plaques
• Plaque clearance: Upon binding, the antibody triggers microglial-mediated clearance of amyloid plaques through Fc receptor-mediated phagocytosis
• Limited peripheral sink: Unlike some other anti-amyloid antibodies, donanemab has limited peripheral binding, which may affect its safety profile[@trailblazer2024]

Amyloid Plaque Removal and Clinical Outcomes

The relationship between amyloid plaque removal and clinical outcomes was one of the key findings from TRAILBLAZER-ALZ 2:

Plaque Reduction:

• Significant reduction in amyloid plaques as measured by PET imaging
• Many participants achieved amyloid negativity (below plaque cutoff threshold)
• Plaque reduction correlated with slower clinical decline

Clinical Benefit:

• Slowing of cognitive decline measured by CDR-SB
• Benefits were most pronounced in participants with lower baseline tau pathology
• Earlier treatment correlated with greater benefit[@kattan2024]

Comparison with Other Anti-Amyloid Therapies

Donanemab operates through a similar mechanism to other anti-amyloid antibodies but has distinct properties:

| Feature | Donanemab | Lecanemab | Aducanumab |
|---------|-----------|-----------|------------|
| Target | pE3-Aβ plaques | Aβ protofibrils | Aβ plaques |
| Dosing interval | Every 4 weeks | Every 2 weeks | Every 4 weeks |
| Plaque removal | High (~80%) | Moderate (~60%) | Variable |
| ARIA risk | Moderate | Lower | Higher |

This comparison shows that while all three antibodies target amyloid, donanemab's specific targeting of pE3-Aβ and its dosing schedule represent distinct characteristics[@vanDyck2024].

TRAILBLAZER-ALZ 2: Phase 3 Results {#results}

Trial Design and Population

TRAILBLAZER-ALZ 2 enrolled 1,736 participants with early symptomatic Alzheimer's disease, defined as:

• Mild cognitive impairment (MCI) due to AD or mild dementia due to AD
• Confirmed amyloid pathology via PET or CSF biomarkers
• Baseline CDR scores of 0.5 or 1.0
• MMSE scores of 20-28

The trial utilized a tau-based enrichment strategy, stratifying participants by baseline tau pathology levels:

• Low-medium tau: Participants with intermediate tau burden
• High tau: Participants with advanced tau pathology

This stratification allowed assessment of treatment effects across different disease stages[@trailblazer2024].

Primary Endpoints

Integrated Alzheimer's Disease Rating Scale (iADRS):
The iADRS is a composite measure combining:

• Cognitive items from the ADAS-Cog
• Functional items from the ADCS-ADL

This endpoint captures both cognitive and functional aspects of disease progression.

Results in Overall Population:

• Treatment with donanemab resulted in 35% slowing of decline on iADRS compared to placebo
• Statistical significance achieved (p<0.001)
• Clinical meaningfulness confirmed by threshold analysis[@donanemab2024]

Results in Low-Medium Tau Population:

• Greater benefit observed in participants with lower baseline tau
• Approximately 36% slowing of decline
• This finding supports early intervention in AD[@seThun2024]

Secondary Endpoints

Key secondary endpoints included:

CDR-SB (Clinical Dementia Rating Sum of Boxes):

• Clinically meaningful slowing of decline observed
• Treatment effect consistent across subgroups

Biomarker Endpoints:

• Significant reduction in amyloid PET standardized uptake value ratio (SUVr)
• Modest slowing of tau PET accumulation
• Reduction in plasma biomarkers (p-tau217)[@lacort2024]

Safety and Tolerability

The safety profile of donanemab was characterized by:

Amyloid-Related Imaging Abnormalities (ARIA):

• ARIA-E (edema): Observed in approximately 24% of treated participants
• ARIA-H (hemorrhosis): Observed in approximately 31% of treated participants
• Most ARIA events were mild to moderate in severity
• ARIA was more common in APOE ε4 carriers
• Most cases were manageable with protocol-defined monitoring[@alloway2024]

Common Adverse Reactions:

• Infusion-related reactions (typically mild)
• Headache
• Falls

Discontinuation:

• Higher dropout rate in treatment arm due to ARIA and other adverse events
• Overall benefit-risk ratio considered favorable by regulatory agencies

FDA Approval and Clinical Implementation {#approval}

FDA Approval Timeline

Donanemab received traditional approval from the FDA in July 2024 under the brand name Kisunla. This approval was based on the TRAILBLAZER-ALZ 2 results demonstrating:

• Clinically meaningful slowing of cognitive decline
• Substantial amyloid plaque reduction
• Favorable benefit-risk profile in early AD population

The approval included specific conditions:

• Indication for early AD (MCI due to AD or mild dementia)
• Required confirmation of amyloid pathology before treatment
• Monitoring requirements for ARIA

Clinical Implementation Considerations

Patient Selection:

• Early-stage patients benefit most
• Amyloid confirmation required
• Consider tau burden for treatment expectations

Monitoring Protocol:

• MRI monitoring at baseline, then as clinically indicated
• Watch for ARIA symptoms (headache, confusion, visual changes)
• APOE ε4 carriers require heightened vigilance

Treatment Duration:

• Treatment can be discontinued upon achieving amyloid negativity
• Periodic assessment of continued benefit
• Long-term effects under investigation[@mattison2024]

Tau PET Imaging and Disease Staging {#tau-imaging}

Role of Tau PET in Donanemab Treatment

Tau PET imaging played a critical role in the TRAILBLAZER-ALZ 2 trial:

Baseline Assessment:

• Allowed stratification of participants by disease stage
• Identified those most likely to benefit from treatment
• Provided baseline for monitoring treatment effects

Treatment Response:

• Showed that donanemab can modestly slow tau accumulation
• Tau changes correlated with clinical outcomes
• Supported the mechanistic link between amyloid removal and downstream effects[@simon2024]

Implications for Clinical Practice

The trial demonstrated that:

• Tau PET can help identify optimal treatment candidates
• Earlier intervention correlates with better outcomes
• Combination of amyloid and tau PET improves patient selection

APOE Genotype and Treatment Response {#apoe}

APOE Effects on Efficacy

APOE ε4 carrier status influenced both response to treatment and risk of side effects:

Efficacy:

• APOE ε4 carriers showed similar treatment benefit to non-carriers
• Subgroup analyses demonstrated consistent effects across genotypes
• Homozygous carriers may require additional monitoring[@bucci2024]

Safety:

• ARIA risk is significantly higher in APOE ε4 carriers
• Homozygous carriers have the highest ARIA risk
• Genotype-informed monitoring protocols are recommended

Related Resources

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Beta](proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT04437511)
• [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT04437511)

References

[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)01306-9)

[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

[Donanemab for early Alzheimer's disease (2024)](https://doi.org/10.1056/NEJMoa2404144)

[TRAILBLAZER-ALZ 2: Donanemab Phase 3 results (2024)](https://doi.org/10.1001/jama-neurol.2024.4000)

[Amyloid removal and clinical outcomes in donanemab treatment (2024)](https://doi.org/10.1016/j.jalz.2024.08.012)

[Tau PET imaging in Alzheimer's disease anti-amyloid therapy (2024)](https://doi.org/10.1093/brain/awae150)

[Amyloid-related imaging abnormalities in donanemab trials (2024)](https://doi.org/10.1111/bcp.16123)

[Lecanemab and donanemab: Comparing anti-amyloid antibodies (2024)](https://doi.org/10.1038/s41591-024-02901-4)

[Donanemab in early Alzheimer's disease (2021)](https://doi.org/10.1056/NEJMoa2100708)

[Biomarker outcomes in TRAILBLAZER-ALZ 2 (2024)](https://doi.org/10.1016/j.jalz.2024.06.018)

[ApoE and anti-amyloid antibody response (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.04.008)

[Subgroup analyses in donanemab TRAILBLAZER-ALZ 2 (2024)](https://doi.org/10.1016/j.trci.2024.09.007)

[Clinical meaningfulness of donanemab treatment effects (2024)](https://doi.org/10.1001/jama.2024.20993)